LDL cholesterol variability in patients with Type 2 diabetes taking atorvastatin and simvastatin

a comparison of two formulae for LDL-C estimation

T. Sathyapalan, Stephen Atkin, E. Kilpatrick

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Background: A new formula was recently proposed by Cordovo et al. that was more highly correlated with low-density lipoprotein (LDL) measured directly than the Friedewald LDL formula. We conducted this prospective study to establish whether the new formula allows true variations in LDL within the same individual to be tracked more closely than that of the Friedewald formula.

Methods: A cross-over study of biological variation of lipids in 26 patients with Type 2 diabetes (T2DM) taking either a short half-life statin, simvastatin 40 mg (n=10), or a long half-life statin, atorvastatin 10 mg. After three months on one statin, fasting lipids were measured on 10 occasions over a five-week period. The same procedure was then followed for the other statin. The LDL was measured by a direct LDL immunoassay and was compared to the LDL estimated by the Friedewald and Cordova (0.7516)×(total cholesterol [TC]-high-density lipoprotein cholesterol [HDL-C]) formulae.

Results: As a group, the calculated or measured mean LDL was no different between statins. However, the biological coefficient of variation (CV) of directly measured LDL was far larger with simvastatin than atorvastatin. This difference was detected by Cordova LDL but not found with the Friedewald LDL formula.

Conclusions: In contrast to Friedewald LDL, Cordova LDL estimation revealed LDL to be much more stable in T2DM patients taking atorvastatin rather than simvastatin that was in accord with LDL when measured directly. Therefore, Cordova LDL which is a measure of non-HDL-cholesterol is the simplest, cheapest and the most convenient measurement for assessment of response to statin treatment.

Original languageEnglish
Pages (from-to)180-182
Number of pages3
JournalAnnals of Clinical Biochemistry
Volume52
Issue number1
DOIs
Publication statusPublished - 19 Jan 2015
Externally publishedYes

Fingerprint

Simvastatin
Medical problems
LDL Lipoproteins
LDL Cholesterol
Type 2 Diabetes Mellitus
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Atorvastatin Calcium
Half-Life
Cholesterol
Lipids
Immunoassay
Cross-Over Studies
HDL Cholesterol

Keywords

  • clinical studies
  • diabetes
  • Lipids

ASJC Scopus subject areas

  • Clinical Biochemistry
  • Medicine(all)

Cite this

LDL cholesterol variability in patients with Type 2 diabetes taking atorvastatin and simvastatin : a comparison of two formulae for LDL-C estimation. / Sathyapalan, T.; Atkin, Stephen; Kilpatrick, E.

In: Annals of Clinical Biochemistry, Vol. 52, No. 1, 19.01.2015, p. 180-182.

Research output: Contribution to journalArticle

@article{3b54bf0db79946af8f12bd1e9e8b4405,
title = "LDL cholesterol variability in patients with Type 2 diabetes taking atorvastatin and simvastatin: a comparison of two formulae for LDL-C estimation",
abstract = "Background: A new formula was recently proposed by Cordovo et al. that was more highly correlated with low-density lipoprotein (LDL) measured directly than the Friedewald LDL formula. We conducted this prospective study to establish whether the new formula allows true variations in LDL within the same individual to be tracked more closely than that of the Friedewald formula.Methods: A cross-over study of biological variation of lipids in 26 patients with Type 2 diabetes (T2DM) taking either a short half-life statin, simvastatin 40 mg (n=10), or a long half-life statin, atorvastatin 10 mg. After three months on one statin, fasting lipids were measured on 10 occasions over a five-week period. The same procedure was then followed for the other statin. The LDL was measured by a direct LDL immunoassay and was compared to the LDL estimated by the Friedewald and Cordova (0.7516)×(total cholesterol [TC]-high-density lipoprotein cholesterol [HDL-C]) formulae.Results: As a group, the calculated or measured mean LDL was no different between statins. However, the biological coefficient of variation (CV) of directly measured LDL was far larger with simvastatin than atorvastatin. This difference was detected by Cordova LDL but not found with the Friedewald LDL formula.Conclusions: In contrast to Friedewald LDL, Cordova LDL estimation revealed LDL to be much more stable in T2DM patients taking atorvastatin rather than simvastatin that was in accord with LDL when measured directly. Therefore, Cordova LDL which is a measure of non-HDL-cholesterol is the simplest, cheapest and the most convenient measurement for assessment of response to statin treatment.",
keywords = "clinical studies, diabetes, Lipids",
author = "T. Sathyapalan and Stephen Atkin and E. Kilpatrick",
year = "2015",
month = "1",
day = "19",
doi = "10.1177/0004563214533515",
language = "English",
volume = "52",
pages = "180--182",
journal = "Annals of Clinical Biochemistry",
issn = "0004-5632",
publisher = "SAGE Publications Ltd",
number = "1",

}

TY - JOUR

T1 - LDL cholesterol variability in patients with Type 2 diabetes taking atorvastatin and simvastatin

T2 - a comparison of two formulae for LDL-C estimation

AU - Sathyapalan, T.

AU - Atkin, Stephen

AU - Kilpatrick, E.

PY - 2015/1/19

Y1 - 2015/1/19

N2 - Background: A new formula was recently proposed by Cordovo et al. that was more highly correlated with low-density lipoprotein (LDL) measured directly than the Friedewald LDL formula. We conducted this prospective study to establish whether the new formula allows true variations in LDL within the same individual to be tracked more closely than that of the Friedewald formula.Methods: A cross-over study of biological variation of lipids in 26 patients with Type 2 diabetes (T2DM) taking either a short half-life statin, simvastatin 40 mg (n=10), or a long half-life statin, atorvastatin 10 mg. After three months on one statin, fasting lipids were measured on 10 occasions over a five-week period. The same procedure was then followed for the other statin. The LDL was measured by a direct LDL immunoassay and was compared to the LDL estimated by the Friedewald and Cordova (0.7516)×(total cholesterol [TC]-high-density lipoprotein cholesterol [HDL-C]) formulae.Results: As a group, the calculated or measured mean LDL was no different between statins. However, the biological coefficient of variation (CV) of directly measured LDL was far larger with simvastatin than atorvastatin. This difference was detected by Cordova LDL but not found with the Friedewald LDL formula.Conclusions: In contrast to Friedewald LDL, Cordova LDL estimation revealed LDL to be much more stable in T2DM patients taking atorvastatin rather than simvastatin that was in accord with LDL when measured directly. Therefore, Cordova LDL which is a measure of non-HDL-cholesterol is the simplest, cheapest and the most convenient measurement for assessment of response to statin treatment.

AB - Background: A new formula was recently proposed by Cordovo et al. that was more highly correlated with low-density lipoprotein (LDL) measured directly than the Friedewald LDL formula. We conducted this prospective study to establish whether the new formula allows true variations in LDL within the same individual to be tracked more closely than that of the Friedewald formula.Methods: A cross-over study of biological variation of lipids in 26 patients with Type 2 diabetes (T2DM) taking either a short half-life statin, simvastatin 40 mg (n=10), or a long half-life statin, atorvastatin 10 mg. After three months on one statin, fasting lipids were measured on 10 occasions over a five-week period. The same procedure was then followed for the other statin. The LDL was measured by a direct LDL immunoassay and was compared to the LDL estimated by the Friedewald and Cordova (0.7516)×(total cholesterol [TC]-high-density lipoprotein cholesterol [HDL-C]) formulae.Results: As a group, the calculated or measured mean LDL was no different between statins. However, the biological coefficient of variation (CV) of directly measured LDL was far larger with simvastatin than atorvastatin. This difference was detected by Cordova LDL but not found with the Friedewald LDL formula.Conclusions: In contrast to Friedewald LDL, Cordova LDL estimation revealed LDL to be much more stable in T2DM patients taking atorvastatin rather than simvastatin that was in accord with LDL when measured directly. Therefore, Cordova LDL which is a measure of non-HDL-cholesterol is the simplest, cheapest and the most convenient measurement for assessment of response to statin treatment.

KW - clinical studies

KW - diabetes

KW - Lipids

UR - http://www.scopus.com/inward/record.url?scp=84918776414&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84918776414&partnerID=8YFLogxK

U2 - 10.1177/0004563214533515

DO - 10.1177/0004563214533515

M3 - Article

VL - 52

SP - 180

EP - 182

JO - Annals of Clinical Biochemistry

JF - Annals of Clinical Biochemistry

SN - 0004-5632

IS - 1

ER -